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Available online 21 October 2015There is an urgent need for better regimens to treat drug-resistant
tuberculosis (DR-TB). Treatment for multi-drug resistant tuberculosis
(MDR-TB, deﬁned as resistance to both isoniazid and rifampicin) has
a success rate of only 64% (Falzon et al., 2013), is prolonged for up to
24 months, and is poorly tolerated. Treatment success for extensively
drug-resistant tuberculosis (XDR-TB, deﬁned as MDR-TB with addi-
tional resistance to ﬂuoroquinolones and an injectable) is only 40%
(Falzon et al., 2013).
The oxazolidinone antimicrobial linezolid, which is registered
for use in Gram-positive bacterial infections, has potentially useful
antimycobacterial activity. Two small randomised controlled trials
(RCTs) of linezolid in patients with XDR-TB have shown improved
rates of sputum culture conversion (Lee et al., 2012; Tang et al., 2015).
However, linezolid is poorly tolerated inDR-TB. Ameta-analysis of linez-
olid use in MDR- and XDR-TB showed that 35% of patients interrupted
linezolid due to toxicity (Zhang et al., 2015). Linezolid causes reversible
myelosuppression and neuropathy, both of which are mediated by a
dose- and time-dependent inhibition ofmitochondrial protein synthesis
(De Vriese et al., 2006). Linezolid's cumulative dose-related toxicity is
a particular problem for patients with DR-TB, who need prolonged
therapy.
In a paper published in this edition of EBioMedicine, Song and col-
leagues (Song et al., 2015) monitored serial mitochondrial function
(cytochrome c oxidase:citrate synthase activity ratio), and correlated
this with both adverse events and trough linezolid concentrations in
participants from their trial of linezolid in XDR-TB (Lee et al., 2012).
Themitochondrial function assay they developed appears to be a useful
surrogate marker of mitochondrial toxicity. Their ﬁnding of a 2 μg/mL
cutpoint for linezolid trough concentrations for toxicity is an importantDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.09.051.
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therapeutic drug monitoring of linezolid in DR-TB.
However, toxicity is only one component of therapeutic drug moni-
toring. We still do not know the optimal linezolid dose or concentra-
tions associated with treatment efﬁcacy in DR-TB. The most widely
used linezolid dose in DR-TB is 600 mg daily, but many patients require
dose reduction to 300 mg daily after developing toxicity. In a meta-
analysis failure rates were almost fourfold higher with the 300 mg
than the 600 mg daily dose (Zhang et al., 2015).
Pharmacokinetic/pharmacodynamic (PK/PD) analyses from the
parent RCT of the study by Song and colleagues demonstrated that plas-
ma concentrations of linezolid were above the minimum inhibitory
concentration (MIC) for each participants' individualMycobacterium tu-
berculosis isolate during the entire dosing interval for nearly all patients
treated with 600 mg daily (Lee et al., 2012). However, nine of 25 pa-
tients treated with 300 mg daily had trough concentrations below the
MIC; two of whom developed linezolid resistance. No association was
found between the time to culture conversion and either the peak or
trough concentrations of linezolid (Lee et al., 2012). The linezolid PK/
PD targets for Gram-positive infections are a free area under
the concentration–time curve (AUC) to MIC ratio of N100 and a time
above MIC of N85% (McGee et al., 2009). A small population pharmaco-
kinetic study of patients with tuberculosis reported that linezolid
600 mg daily achieved a free AUC/MIC ratio of N100, but time above
MIC was only 63% (McGee et al., 2009). A PK/PD modelling study,
using published data from linezolid studies performed in persons with-
out tuberculosis, estimated that doses of 300 mg once daily, 300 mg
twice daily, and600mg once dailywere associatedwithmedian percent
of time with free linezolid concentrations N2 times the MIC of 1 mg/L
(the suggested threshold for development of linezolid resistance) of
56%–100%, 100%, and 78%–100%, respectively; and the median percent
of time above a concentration N 3.36 mg/L (the suggested threshold as-
sociated with neurologic toxicity) was 20%, 55%, and 40%, respectively
(Barry et al., 2014). Linezolid's toxicity threshold thus appears to be
very close to the efﬁcacy threshold for tuberculosis.
Clearly, much more work remains to be done before linezolid can
be recommended for widespread use in DR-TB. The combined total
of participants in both RCTs of linezolid for XDR-TB is only 106, and
both trials were done in East Asia. There may be important host fac-
tors affecting toxicity and efﬁcacy in other regions. The high propor-
tion of DR-TB patients who develop cumulative dose-related toxicity
on linezolid suggests that its use should be for a limited period of
time in an intensive phase, like the aminoglycosides. The optimal
dose and duration of linezolid remains to be determined, especiallythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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delamanid. Prospective data evaluating both the concentration thresh-
old associated with toxicity and the concentrations needed
to maximize antimycobacterial activity when combined with other
agents are needed in patients with DR-TB. Alternative oxazolidinones
with potential formore favourable risk:beneﬁt ratios also need to be ex-
plored for use in DR-TB. For example, tedizolid, which is active against
M. tuberculosis (Vera-Cabrera et al., 2006), appears to have less mito-
chondrial toxicity than linezolid (Flanagan et al., 2015). Finally,
implementing linezolid for DR-TB in resource-limited settings, where
the burden is greatest, will require dramatic price reductions and
training for toxicity monitoring. Therapeutic drug monitoring will be
difﬁcult to implement in these settings.
Disclosure
GM has acted as a consultant to Merck, who market tedizolid. CAB
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